Gabapentin Tablet, Film Coated
Product Images NDC 70518-2323

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 70518-2323). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin 800mg 70518 2323 01

Gabapentin 800 mg film-coated tablets in a quantity of 90. The label shows the proprietary name Gabapentin, strength 800 mg, and dosage form as tablets. It includes NDC 70518-2323-01, notes the manufacturer as Aurobindo Pharma in Hyderabad, India, and repackaging information by RemedyRepack Inc. Directions instruct to see the package insert, with storage temperature details and a reminder to keep medication out of children's reach.*

FDA Label Image

Gabapentin 800mg 70518 2323 02

Gabapentin 800 mg film-coated tablets in a pack containing 180 tablets. The label shows it is for prescription use only and is repackaged by RemedyRepack Inc. Directions advise consulting the package insert. The original manufacturer is Aurobindo Pharma, Hyderabad, India.*

FDA Label Image

Gabapentin 800mg 70518 2323 03

Gabapentin 800 mg film-coated tablets, labeled for oral use, with a quantity of 120 tablets. The label includes the product NDC 70518-2323-03 and mentions repackaging by RemedyRepack Inc. It also displays storage instructions, a caution to keep out of reach of children, and manufacturing details from Aurobindo Pharma, Hyderabad, India. The label has a purple and black text design with a QR code present.*

FDA Label Image

Remedy_label (Remedy Label)

Gabapentin 800 mg oral film-coated tablets packaging label showing quantity of 30 tablets. The label includes NDC 70518-2323-00, manufacturer Aurobindo Pharma, and repackager RemedyRepack Inc. in Indiana. Storage instructions and a QR code are visible.*

FDA Label Image

Creatinine Clearance (Gabapentin Fig1)

This image shows a formula for calculating creatinine clearance (CLCr). It incorporates age in years, weight in kilograms, serum creatinine in mg/dL, and includes a factor adjustment for female patients (0.85). It is a text-based medical calculation formula.*

FDA Label Image

Figure 1. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 1 (Gabapentin Fig2)

A line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 1' depicting mean pain score on the vertical axis and weeks (Baseline to 8) on the horizontal axis. It compares placebo and Gabapentin 3600 mg/day, showing pain score trends over two periods labeled '4-Week Dose Titration Period' and '4-Week Fixed Dose Period'.*

FDA Label Image

Figure 2. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (Gabapentin Fig3)

A line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 2' showing mean pain scores over 7 weeks. The graph compares placebo and gabapentin at 1800 mg/day and 2400 mg/day across a 3-week dose titration period and a 4-week fixed dose period. Pain scores decrease more with gabapentin than placebo over time.*

FDA Label Image

Figure 3. Proportion Of Responders (patients With ≥50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (Gabapentin Fig4)

A bar graph titled 'Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies.' It compares responder proportions in two studies between placebo (PBO) and Gabapentin (GBP) doses (3600 mg in Study 1; 1800 mg and 2400 mg in Study 2), with percentages noted above bars and significance levels indicated by asterisks.*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Gabapentin Fig5)

A scatter plot chart showing responder rates in patients receiving Gabapentin as differences from placebo by dose and study for adjunctive therapy in patients aged 12 years and older with partial seizures. The x-axis represents daily dose in milligrams, and the y-axis represents the percentage difference in responder rate. Data points from three different studies are plotted at various doses, ranging from 600 to 1800 mg daily.*

FDA Label Image

Chemical Structure (Gabapentin Str)

Chemical structure of Gabapentin, showing its cyclohexane ring with attached amino (CH2NH2) and carboxymethyl (CH2CO2H) groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.